Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Closed to Accrual

Canadian Cancer Trials Group BR.28 (MLG CONVERT) - Concurrent ONce-daily VErsus twice-daily RadioTherapy: A 2-Arm Randomized Controlled Trial of Concurrent Chemo-Radiotherapy Comparing Twice-daily and Once-daily Radiotherapy Schedules in Patients with Limited Stage Small Cell Lung Cancer (SCLC) and Good Performance Status - has met its accrual goal and was closed to further accrual as of July 22, 2013.

This was an intergroup radiation study and Canadian Cancer Trials Group centres contributed 41 patients (7.7% of overall accrual). The final Canadian patient was randomized in July 2013 and all patients will have completed treatment by December 31, 2013.

Thanks goes out to all participating centres, staff and patients for their contribution to the success of the trial.